Literature DB >> 2422942

Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.

K Sheibani, H Battifora, J S Burke.   

Abstract

To evaluate the usefulness of an immunohistologic approach to the differential diagnosis of mesothelioma and pulmonary adenocarcinoma, the authors studied paraffin-embedded, fixed tissue sections from 50 primary adenocarcinomas of the lung and 28 mesotheliomas of the pleura by using a panel of monoclonal antikeratin, antihuman milk fat globule (HMFG-2), anti-Leu M1, and monoclonal anticarcinoembryonic antigen (CEA) antibody; we also used a conventional heterologous anti-CEA antiserum with and without prior absorption with spleen powder to remove antibodies to nonspecific cross-reacting antigen (NCA). Keratin was present in both mesotheliomas and adenocarcinomas and did not help in distinguishing between these two neoplasms. HMFG-2 was detected in 48 (96%), and Leu M1 was positive in 47 (94%) of the adenocarcinomas, but not in any of the mesotheliomas. By using conventional rabbit antiserum, the authors detected CEA in the majority of adenocarcinomas (96%), but also in two cases of mesothelioma. When the anti-CEA antiserum was absorbed with NCA, the number of positively reacting adenocarcinomas decreased considerably to 76%; however, after this treatment, none of the mesotheliomas gave positive reactions. The monoclonal anti-CEA antibody was reactive in 36 of the adenocarcinomas (72%), but in none of the mesotheliomas. Our results indicate that, in addition to HMFG-2 and CEA, the expression of Leu M1 antigen by most primary pulmonary adenocarcinoma (94%) and its absence in mesothelioma could be used as a valuable marker for primary adenocarcinoma of the lung that involves the pleura and permits its differentiation from mesothelioma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2422942      PMCID: PMC1888323     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  23 in total

1.  Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach.

Authors:  H Battifora; M I Kopinski
Journal:  Cancer       Date:  1985-04-15       Impact factor: 6.860

2.  Contribution of electron microscopy to the diagnosis of pleural mesothelioma.

Authors:  P Stoebner; J F Bernaudin; M Nebut; F Basset
Journal:  Ann N Y Acad Sci       Date:  1979       Impact factor: 5.691

3.  Electron microscopy in the diagnosis of pleural mesotheliomas.

Authors:  N S Wang
Journal:  Cancer       Date:  1973-05       Impact factor: 6.860

4.  A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  Am J Clin Pathol       Date:  1981-05       Impact factor: 2.493

5.  Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture.

Authors:  J Taylor-Papadimitriou; J A Peterson; J Arklie; J Burchell; R L Ceriani; W F Bodmer
Journal:  Int J Cancer       Date:  1981-07-15       Impact factor: 7.396

6.  Absence of carcinoembryonic antigen-like material in mesothelioma: an immunohistochemical differentiation from other lung cancers.

Authors:  N S Wang; S N Huang; P Gold
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860

7.  Detection of tissue CEA-like substance as an aid in the differential diagnosis of malignant mesothelioma.

Authors:  D Whitaker; G F Sterrett; K B Shilkin
Journal:  Pathology       Date:  1982-07       Impact factor: 5.306

8.  Malignant mesothelioma: ultrastructural distinction from adenocarcinoma.

Authors:  M J Warhol; W F Hickey; J M Corson
Journal:  Am J Surg Pathol       Date:  1982-06       Impact factor: 6.394

9.  Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas.

Authors:  J M Corson; G S Pinkus
Journal:  Am J Pathol       Date:  1982-07       Impact factor: 4.307

10.  Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis. Evaluation of the application of morphometry combined with histochemistry and immunostaining.

Authors:  W S Kwee; R W Veldhuizen; R P Golding; H Mullink; J Stam; R Donner; M E Boon
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982
View more
  14 in total

1.  Tonsillar mapping of determinants found on normal lymphoreticular (T,B,K, immature and macrophage) and myeloblastic leukemia cells.

Authors:  E M McMillan; L Stoneking; G B Humphrey; J Rapacz
Journal:  Am J Pathol       Date:  1987-03       Impact factor: 4.307

2.  Prognostic significance of Leu-M1 immunostaining in papillary carcinomas of the thyroid gland.

Authors:  S Schröder; W Schwarz; W Rehpenning; T Löning; W Böcker
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

3.  HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura.

Authors:  A D Kennedy; G King; K M Kerr
Journal:  J Clin Pathol       Date:  1997-10       Impact factor: 3.411

4.  Distinction between cells in serous effusions using a panel of antibodies.

Authors:  A F Lauritzen
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

5.  Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.

Authors:  T Kawai; S D Greenberg; L D Truong; C A Mattioli; M Klima; J L Titus
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

6.  Primary peritoneal serous papillary carcinoma: a clinical and pathological study.

Authors:  Qi Liu; Jing-xian Lin; Qun-li Shi; Bo Wu; Heng-hui Ma; Gui-qin Sun
Journal:  Pathol Oncol Res       Date:  2011-06-07       Impact factor: 3.201

7.  Leu-M1 immunoreactivity and prognosis in medullary carcinomas of the thyroid gland.

Authors:  S Schröder; W Schwarz; W Rehpenning; H Dralle; V Bay; W Böcker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

8.  Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.

Authors:  H Moch; M Oberholzer; P Dalquen; W Wegmann; F Gudat
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

9.  Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages.

Authors:  Derya Gümürdülü; E Handan Zeren; Philip T Cagle; Fazilet Kayasel uk; Nazan Alparslan; Ali Kocabas; Ilhan Tuncer
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

10.  ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.

Authors:  C J O'Hara; J M Corson; G S Pinkus; R A Stahel
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.